Welcome to our dedicated page for Mei Pharma news (Ticker: MEIP), a resource for investors and traders seeking the latest updates and insights on Mei Pharma stock.
MEI Pharma Inc (MEIP) is a clinical-stage biopharmaceutical company focused on developing novel oncology therapies, with an emphasis on oral treatments targeting specific cancer mechanisms. This page provides investors and industry observers with timely updates on the company’s clinical trials, regulatory milestones, financial performance, and strategic partnerships.
As a centralized resource for MEI Pharma news, this page aggregates press releases, earnings reports, and scientific updates related to its pipeline candidates including zandelisib (PI3K delta inhibitor) and ME-344 (mitochondrial inhibitor). Users can track progress across clinical development stages, from Phase 1 safety data to late-stage trial results.
The curated news collection serves investors seeking to monitor MEIP’s operational progress, partnership announcements with pharmaceutical companies, and presentations at major medical conferences. Content is organized chronologically and categorized for efficient navigation, ensuring stakeholders stay informed about developments impacting the company’s valuation and scientific trajectory.
Bookmark this page for direct access to MEI Pharma’s official communications, including FDA correspondence updates and analyses of trial data. Regular visitors gain a comprehensive view of the company’s position within the competitive oncology therapeutics sector without promotional bias.
MEI Pharma, Inc. (NASDAQ: MEIP) reported Q3 results for the period ended March 31, 2021, revealing a net loss of $31.3 million, or $0.28 per share, compared to a loss of $4.3 million, or $0.04 per share the previous year. Revenue increased to $2.4 million from $1.2 million, largely due to a license agreement with Kyowa Kirin. Key advancements include the completion of enrollment in the TIDAL study for zandelisib and promising preclinical data for voruciclib. The company has $164.6 million in cash with no debt and aims to submit data to the FDA for accelerated approval by year-end.
MEI Pharma, Inc. (NASDAQ: MEIP) announced the retirement of its chief medical officer, Robert Mass, effective May 3, 2021. Dr. Mass, who joined MEI in 2010, will serve as a strategic advisor post-retirement. Richard Ghalie, previously senior vice president of clinical development, has been promoted to chief medical officer. Under Ghalie's leadership, MEI's zandelisib program has progressed significantly, with plans for a new drug application to the FDA under the accelerated approval pathway.
MEI Pharma, Inc. (NASDAQ: MEIP) and Kyowa Kirin Co., Ltd. have completed enrollment in the follicular lymphoma primary efficacy population for the global Phase 2 TIDAL study. This study evaluates zandelisib, a potential cancer treatment. The primary efficacy population includes 91 patients with follicular lymphoma and 64 with marginal zone lymphoma. Topline data is expected in Q4 2021, with plans to submit for FDA accelerated approval. Zandelisib holds Fast Track designation for adult patients with relapsed follicular lymphoma who have undergone at least two prior systemic therapies.
MEI Pharma, Inc. (NASDAQ: MEIP) announced promising preclinical data for voruciclib, a CDK9 inhibitor, showing its effectiveness against KRAS mutant cancers. The findings, presented at the AACR Annual Meeting 2021, reveal voruciclib's ability to inhibit MYC and synergistically enhance the efficacy of KRAS inhibitors. Currently in a Phase 1b trial for B-cell malignancies and AML, the data supports the potential for voruciclib as a new treatment option. The company plans to further explore synergistic combinations and will host a webcast on April 13, 2021, to discuss the findings and company updates.
MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company, announced its participation in the 20th Annual Needham Virtual Healthcare Conference. The company will present a comprehensive overview and business update on April 12, 2021, at 12:45 p.m. Eastern Time. A live webcast can be accessed via MEI Pharma's website, with an archived replay available for 30 days post-event. MEI is focused on developing innovative cancer therapies, including zandelisib, currently in Phase 2 trials, aiming for FDA accelerated approval.
MEI Pharma, Inc. (NASDAQ: MEIP) announced that its abstract on Voruciclib, a CDK9 inhibitor, was selected for an E-Poster Session at the AACR Annual Meeting 2021, set for April 10, 2021. Voruciclib targets KRAS mutant cancers by downregulating MYC, which is crucial for cancer cell proliferation. Preclinical studies demonstrated reduced cell viability and significant tumor growth inhibition. MEI is also conducting additional studies to evaluate Voruciclib's synergistic effects with other KRAS inhibitors. This positions Voruciclib as a potential therapeutic option for challenging KRAS-driven cancers.
MEI Pharma (NASDAQ: MEIP) has confirmed its participation in the virtual H.C. Wainwright Global Life Sciences Conference 2021. The event will feature a company overview and business update, available for on-demand listening starting March 9, 2021, at 7:00 a.m. Eastern Time. This presentation will be archived for 90 days on MEI Pharma's website. The company is focused on developing new cancer therapies, including zandelisib, which is currently in a Phase 2 clinical trial potentially supporting FDA approval.
MEI Pharma (NASDAQ: MEIP) reported its financial results for the quarter ending December 31, 2020, showing significant developments in its zandelisib program. Cash and equivalents stood at $180.1 million, aided by $20.9 million from a tax refund. Revenue increased to $9.2 million from $1.0 million year-over-year, mainly due to a licensing agreement with Kyowa Kirin. Research and development expenses rose to $22.2 million, with a net loss of $11.5 million, improving from $20.2 million the previous year. The company anticipates important milestones for zandelisib in 2021.
MEI Pharma, Inc. (NASDAQ: MEIP) announced the completion of the safety evaluation phase in its Phase 1b trial for zandelisib, a selective PI3K delta inhibitor, in combination with zanubrutinib for B-cell malignancies. The Safety Review Committee recommended expanding into disease-specific cohorts, confirming the treatment was well tolerated. MEI also updated its 2021 pipeline milestones, including anticipated enrollment completion in the Phase 2 TIDAL study and initiation of further studies for zandelisib, voruciclib, and ME-344. The company has sufficient cash runway through 2023.
MEI Pharma, Inc. (NASDAQ: MEIP) reported its Q1 FY2021 results, highlighting a cash position of $176.1 million with no debt and a net loss of $2.1 million, or $0.02 per share. Revenues increased to $3.8 million from $1.2 million YoY, mainly due to a license agreement with Kyowa Kirin. R&D expenses rose to $13.0 million, driven by zandelisib development. The TIDAL study for follicular lymphoma is on track for enrollment completion by Q1 2021, with additional studies planned for expansion. The company remains committed to advancing its clinical pipeline amid the ongoing pandemic.
FAQ
What is the current stock price of Mei Pharma (MEIP)?
What is the market cap of Mei Pharma (MEIP)?
